Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Enhanced plasma factor VIII activity in mice via cysteine mutation using dual vectors.

Science China. Life sciences - 1 Jun 2012

Zhu Fuxiang, Liu Zelong, Miao Jing, Qu Huige, Chi Xiaoyan

Abstract excerpt

Hemophilia A is caused by a genetic mutation in coagulation factor VIII (FVIII) gene and gene therapy is considered to be a promising strategy for its treatment. We recently demonstrated that co-delivery of two vectors expressing M662C mutated heavy and D1828C mutated light chain genes of B-domain-deleted coagulation factor VIII (BDD-FVIII) leads to inter-chain disulfide cross-linking and improved heavy chain...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenoviridae
Share to Cysteine
Share to Cytomegalovirus

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Factor VIII

Share to Genetic Therapy

Share to Genetic Vectors

Share to Hemophilia A

Share to Peptide Fragments

Source

Identifiers

PMID: 22744182
DOI: 10.1007/s11427-012-4333-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enhanced plasma factor VIII activity in mice via cysteine mutation using dual vectors.PMID 22744182Read ↗

Inter-chain disulfide bond improved protein trans-splicing increases plasma coagulation activity in C57BL/6 mice following portal vein FVIII gene delivery by dual vectors.Semantic proximity Read ↗

Enhanced factor VIII heavy chain for gene therapy of hemophilia A.Semantic proximity Read ↗

Engineered coagulation factor VIII with enhanced secretion and coagulation potential for hemophilia A gene therapySemantic proximity Read ↗

Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII.Semantic proximity Read ↗

Efficient Production of Dual Recombinant Adeno-Associated Viral Vectors for Factor VIII DeliverySemantic proximity Read ↗

Activated Factor X delivered by Adeno-Associated virus significantly inhibited bleeding and alleviated hemophilia A/B arthropathy in hemophilia miceSemantic proximity Read ↗

Long-term correction of hemophilia A mice following lentiviral mediated delivery of an optimized canine factor VIII gene.Semantic proximity Read ↗

[Trans-splicing of Cys mutated coagulation factor VIII].Semantic proximity Read ↗

Murine tissue factor disulfide mutation causes a bleeding phenotype with sex specific organ pathology and lethality.Semantic proximity Read ↗

Lentiviral Vector Platform for Production of Bioengineered Recombinant Coagulation Factor VIIISemantic proximity Read ↗

Transgenic mice can express mutant human coagulation factor IX with higher level of clotting activity.Semantic proximity Read ↗

In vivo production of functional single-chain Fv fragment with an N-terminal-specific bio-orthogonal reactive group.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.